ValuEngine upgraded shares of EXACT Sciences (NASDAQ:EXAS) from a buy rating to a strong-buy rating in a report released on Wednesday.
Other analysts have also issued reports about the company. Benchmark set a $65.00 price target on EXACT Sciences and gave the stock a buy rating in a research note on Wednesday, January 17th. Zacks Investment Research raised EXACT Sciences from a hold rating to a buy rating and set a $62.00 price target on the stock in a research note on Tuesday, January 16th. William Blair reaffirmed a buy rating on shares of EXACT Sciences in a research note on Wednesday, January 10th. Bank of America set a $67.00 price target on EXACT Sciences and gave the stock a buy rating in a research note on Monday, January 8th. Finally, Leerink Swann set a $67.00 price target on EXACT Sciences and gave the stock a buy rating in a research note on Friday, February 23rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $53.84.
EXAS traded up $0.53 during trading on Wednesday, hitting $49.61. The company’s stock had a trading volume of 1,862,176 shares, compared to its average volume of 2,754,551. The company has a current ratio of 15.30, a quick ratio of 14.86 and a debt-to-equity ratio of 0.71. EXACT Sciences has a twelve month low of $29.45 and a twelve month high of $63.60. The firm has a market cap of $5,982.77, a P/E ratio of -50.11 and a beta of 0.86.
EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Thursday, April 26th. The medical research company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.05. The company had revenue of $90.30 million for the quarter, compared to analyst estimates of $86.31 million. EXACT Sciences had a negative return on equity of 20.92% and a negative net margin of 38.61%. EXACT Sciences’s quarterly revenue was up 86.7% compared to the same quarter last year. During the same period last year, the company earned ($0.32) earnings per share. equities research analysts forecast that EXACT Sciences will post -1.11 EPS for the current year.
In other EXACT Sciences news, insider Kevin T. Conroy sold 101,488 shares of the business’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $45.72, for a total transaction of $4,640,031.36. Following the transaction, the insider now owns 931,540 shares of the company’s stock, valued at $42,590,008.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP D Scott Coward sold 4,420 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $42.34, for a total value of $187,142.80. The disclosure for this sale can be found here. Insiders have sold 229,834 shares of company stock worth $10,341,366 in the last three months. 4.00% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EXAS. Dimensional Fund Advisors LP raised its position in EXACT Sciences by 82.4% in the third quarter. Dimensional Fund Advisors LP now owns 203,145 shares of the medical research company’s stock valued at $9,571,000 after purchasing an additional 91,794 shares during the period. Cubist Systematic Strategies LLC raised its position in EXACT Sciences by 375.1% in the third quarter. Cubist Systematic Strategies LLC now owns 4,276 shares of the medical research company’s stock valued at $201,000 after purchasing an additional 3,376 shares during the period. Crow Point Partners LLC purchased a new stake in EXACT Sciences in the fourth quarter valued at $145,000. Schwab Charles Investment Management Inc. raised its position in EXACT Sciences by 5.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 765,522 shares of the medical research company’s stock valued at $40,221,000 after purchasing an additional 41,784 shares during the period. Finally, Appleton Group LLC purchased a new stake in EXACT Sciences in the fourth quarter valued at $220,000. 82.32% of the stock is currently owned by institutional investors.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.